Top feature box IMAGE ONLY - COMPANY NEWS
 |
Press Releases
Cardinal Health Signs Preferred Provider Agreement With Child Health Corporation Of America For Pyxis® Products
09/21/2005
SAN DIEGO, Sept. 21, 2005 – Cardinal Health, Inc. (NYSE: CAH), the leading provider of products and services supporting the health care industry, has signed a new preferred provider agreement with Child Health Corporation of America (CHCA) for its Pyxis® medication and supply management products.
“We’re pleased that CHCA has again selected Pyxis® Products as the preferred provider of automation technology,” said Dwight Winstead, president and chief operating officer of the Clinical Technologies and Services segment of Cardinal Health. “Our proven medication and supply management solutions will help drive safety and efficiencies at these facilities, allowing them to provide better care for their pediatric patients.”
The renewal agreement extends through April 30, 2008 and includes the full suite of market-leading Pyxis® medication and supply management systems including the:
-
Pyxis® Anesthesia System for secure medication and supply management
-
Pyxis MedStation® 3000 automated medication management system
-
Pyxis® Connect physician order management system
-
Pyxis SupplyStation® secure inventory management system
“CHCA’s group purchasing services help children’s hospitals gain access to the right products and services at the right price,” said Mike Bomstad, vice president of purchasing services for Child Health Corporation of America. “We made a decision to go with a dual-source agreement to supply our members with the best price possible for their preferred provider. However, the majority of our facilities already use Pyxis® products, and the new agreement creates a strong incentive for CHCA owners to continue to do so.”
Children’s Hospital Boston, a member of CHCA, maintains a strong, ongoing relationship with Cardinal Health, Pyxis® Products. ”We use the Pyxis MedStation® system to automate and streamline our medication management process,” said Al Patterson, director of pharmacy for Children’s Hospital Boston. “Our Pyxis MedStation® system has dramatically improved workflow while helping us improve patient safety and meet JCAHO standards, which in the end really means better patient care.”
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $75 billion, global company serving the health-care industry with a broad portfolio of products and services. It manufactures and distributes pharmaceuticals and medical supplies, offers a range of clinical services and develops automation products that improve the management and delivery of supplies and medication for hospitals, physician offices and pharmacies. Through this diverse offering, Cardinal Health delivers integrated health-care solutions that help customers reduce their costs, improve efficiency and deliver better care to patients. Ranked No. 16 on the Fortune 500, Cardinal Health employs more than 55,000 people on six continents. More information about the company may be found at www.cardinalhealth.com.
Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: the costs, difficulties, and uncertainties related to the integration of acquired businesses; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; changes in the distribution patterns or reimbursement rates for health-care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal and administrative proceedings; the impact of previously announced restatements; difficulties or delays in implementing its global restructuring program; difficulties in opening new facilities or fully utilizing existing capacity; difficulties and uncertainties associated with business model transitions, including the conversion of margin generated from branded pharmaceutical manufacturers to non-contingent consideration; and general economic and market conditions. Cardinal Health undertakes no obligation to update or revise any forward-looking statement.
